HC Wainwright & Co. Maintains Buy on Inhibrx Biosciences, Lowers Price Target to $220
Benzinga Newsdesk 20 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Robert Burns maintains Inhibrx Biosciences (NASDAQ:INBX) with a Buy and lowers the price target from $245 to $220.
HC Wainwright & Co. analyst Robert Burns maintains Inhibrx Biosciences (NASDAQ:INBX) with a Buy and lowers the price target from $245 to $220.
